Clinical Trials · NCT02111044
Phase II Study With ITF2984 in Acromegalic Patients
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Italfarmaco
- Enrollment
- 48
- Start date
- Apr 2014
- Locations
- 26 sites, 9 countries
- Primary endpoint
- effect of treatment on GH and IGF-1